LEADER 05286nam 2200649 450 001 9910459795003321 005 20200520144314.0 010 $a0-12-800485-1 010 $a0-12-800039-2 035 $a(CKB)3710000000312778 035 $a(EBL)1887727 035 $a(SSID)ssj0001455337 035 $a(PQKBManifestationID)11792253 035 $a(PQKBTitleCode)TC0001455337 035 $a(PQKBWorkID)11392437 035 $a(PQKB)10664064 035 $a(MiAaPQ)EBC1887727 035 $a(Au-PeEL)EBL1887727 035 $a(CaPaEBR)ebr10999493 035 $a(CaONFJC)MIL732169 035 $a(OCoLC)898069526 035 $a(EXLCZ)993710000000312778 100 $a20150110h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aInflammation in heart failure /$fedited by Matthijs Blankesteijn, Raffaele Altara 210 1$aLondon, England :$cAcademic Press,$d2015. 210 4$dİ2015 215 $a1 online resource (221 p.) 300 $aDescription based upon print version of record. 311 $a1-336-00887-3 320 $aIncludes bibliographical references and index. 327 $aFront Cover; Inflammation in Heart Failure; Copyright; Contents; Contributors; Preface; Section 1: Pathophysiology of the Inflammatory Response in Heart Failure; Chapter 1: Inflammation in Heart Failure with Preserved Ejection Fraction; 1.1. Introduction; 1.2. Consequences of Limited Understanding of Pathophysiology in HFpEF; 1.3. Underlying Causes of HFpEF; 1.4. Adaptive Mechanisms in HFpEF; 1.5. Inflammation in HFpEF; 1.5.1. Inflammation in HFpEF Animal Studies; 1.5.1.1. Interactions with Other Systems; 1.5.2. Inflammation in HFpEF Human Studies 327 $a1.6. Oxidative Stress, Endothelial Dysfunction and Microvascular Disease1.6.1. Potential Implications for Treatment of HFpEF; 1.7. Conclusions; References; Chapter 2: Role of the Innate Immune System in Ischemic Heart Failure; 2.1. Introduction; 2.2. Initiation of the Immune Response; 2.2.1. Receptors; 2.2.2. Complement; 2.2.3. Oxidative Stress; 2.2.3.1. ROS Generation Post- MI ; 2.2.3.2. Role of Oxidative Stress for Cardiac Necrosis and Inflammation; 2.2.4. Mechanical Stimuli; 2.3. Effectors of Innate Immunity; 2.3.1. Cytokines; 2.3.1.1. Cytokine Effects on Cardiomyocyte Survival 327 $a2.3.1.2. Cytokines Influence Granulation Tissue Formation and Vascular Remodeling Post-injury2.3.1.3. Cytokines Modulate Scar Tissue Formation After Injury; 2.3.1.4. Cytokines and ROS ; 2.3.1.5. Cytokines in Inflammation Resolution; 2.3.2. Cellular Effectors; 2.3.2.1. Leukocyte Recruitment; 2.3.2.2. Neutrophils; 2.3.2.2.1. Neutrophil-Mediated Cardiac Injury; 2.3.2.2.1.1. Reactive Oxygen Species; 2.3.2.2.1.2. Granule Toxicity; 2.3.2.3. Mononuclear Cells; 2.3.2.3.1. Monocytes; 2.3.2.3.2. Macrophages; 2.4. Reverse Remodeling 327 $a2.5. Clinical Implications: Is There a Causal Link Between Dysequilibrated Inflammation and Remodeling?References; Chapter 3: The Role of Inflammation in Myocardial Infarction; 3.1. Introduction; 3.2. Role of the Inflammatory Response Before MI; 3.2.1. Development of the Atherosclerotic Plaque; 3.2.2. Immune Cells Involved; 3.2.3. Maturation and Rupture of the Atherosclerotic Plaque; 3.3. The Role of the Inflammatory Response in MI; 3.3.1. MI and Wound Healing; 3.3.2. Humoral Immune Response Post-MI; 3.3.2.1. Cytokines; 3.3.2.2. Chemokines; 3.3.3. Cellular Immune Response Post-MI 327 $a3.3.3.1. Leukocytes3.3.3.2. Monocytes; 3.3.3.3. Macrophages; 3.3.3.4. Nonimmune Cells; 3.3.4. Other Factors Modulating the Immune Response Post-MI; 3.4. Inflammation as a Pharmacological and Biocellular Target; 3.4.1. Therapy Aimed at Inflammation Before MI; 3.4.1.1. Current Pharmacotherapy Targeting Inflammation Before MI; 3.4.1.1.1. Statins; 3.4.1.1.2. Hypoglycemic Agents; 3.4.1.1.3. Renin Angiotensin System Targeting; 3.4.1.1.4. P2Y 12 Receptor Inhibitors; 3.4.1.2. Novel Strategies Targeting Inflammation Before MI; 3.4.2. Therapy Aimed at Inflammation After MI 327 $a3.4.2.1. Current Pharmacotherapy Targeting Inflammation After MI 330 $aInflammation in Heart Failure, edited by W. Matthijs Blankesteijn and Raffaele Altara, is the first book in a decade to provide an in-depth assessment on the causes, symptoms, progression and treatments of cardiac inflammation and related conditions. This reference uses two decades of research to introduce new methods for identifying inflammatory benchmarks from early onset to chronic heart failure and specifically emphasizes the importance of classifying at-risk subgroups within large populations while determining the patterns of cytokines in such classifications. Further, the book details c 606 $aHeart failure$xDiagnosis 606 $aInflammation$xAlternative treatment 608 $aElectronic books. 615 0$aHeart failure$xDiagnosis. 615 0$aInflammation$xAlternative treatment. 676 $a616.129 702 $aBlankesteijn$b Matthijs 702 $aAltara$b Raffaele 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910459795003321 996 $aInflammation in heart failure$92172481 997 $aUNINA